MapLight Therapeutics, Inc.
ML-021
Parkinson’s Disease
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for ML-021 (Parkinson’s Disease) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 14h ago
“Complete IND-enabling studies in 2H 2026”